A Novel Treatment of Schistosomiasis: Nano-Calcium Silicate Incorporating 5% Copper Oxide

Mohamed Fathallah Abou El-Nouri¹, Sayed Hamed Kenawy²,², Gehan T. El-Bassyouni², Esmat Mahmoud Aly Hamzawy*¹

¹Department of Zoology, Faculty of Science, Al-Azhar University, Nasr City 11884, Cairo, Egypt.
²Refractories, Ceramics and Building Materials Department, National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt.
³Imam Mohamed Ibn Saud Islamic University (IMSIU), Collage of Science, Chemistry Dept. Riyadh 11623, Saudi Arabia.
⁴Glass Research Department, National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt.

Article info

Article History:
Received: 23 Jan. 2020
Revised: 18 Mar. 2020
Accepted: 16 Apr. 2020
epubhlished: 7 Nov. 2020

Keywords:
• Anti-schistosomal activity
• CS-5%CuO-containing calcium silicate
• S. mansoni
• S. haematobium

Abstract

Purpose: Praziquantel (PZQ) is a well-known drug accredited by the World Health Organization (WHO) for the treatment of schistosomiasis. It shows poor efficiency in patients during the earliest infection phases. Therefore, the search for new alternative drugs was the intention of many researchers.

Methods: In the current study, the effect of different concentrations (ranging from 0.07-10 μg/mL) of calcium silicate (CS) containing 5% copper oxide (CS-5%CuO) on golden hamster infected by Schistosoma mansoni and Schistosoma haematobium (Egyptian strains) was evaluated in both in vitro and in vivo. To the best of our knowledge, this is a novel study in investigating the efficiency of CS-5%CuO against both strains of schistosomes. The worms of S. mansoni and S. haematobium were tested in RPMI-1640 medium in vitro.

Results: The results declare that CS-5% CuO exhibited excellent anti-schistosomal activities on both in vitro and in vivo experiments for both Egyptians Schistosoma strains. The most potential effect of the CS-5% CuO was exhibited after 10 μg/mL with significant activity of (P value = 0.001).

Conclusion: Therefore, CS-5%CuO may become an innovative treatment for the schistosomiasis.

Introduction

Schistosomiasis is a highly demolishing tropical disease and is a devastating source of illness in underdeveloped countries.¹ Bilharziasis is considered a water-born trematodiasis which uses fresh water snails as an intermediate host. There are three main strains infecting humans; Schistosoma mansoni, Schistosoma haematobium and Schistosoma japonicum.² Such strains are parasitic flukes (trematodes) in the genus Schistosoma, found in tropical areas and lead to chronic kidney disease. Schistosomiasis has acute and chronic phases. The acute phase is often short-term and develops in a mild form few weeks following the penetrating of the schistosome parasite through the skin of the host. Unless treated, schistosomiasis may develop into a chronic inflammation which progresses slowly into swelling, fibrosis and necrosis of the affected abdominal viscera.³

Mass drug administration in endemic areas using Praziquantel (PZQ) (quinolone derivative) represents a key necessity for schistosomiasis control programs.⁴ It was used to treat millions of people and it was planned to extend over 235 million people by 2015.⁵ PZQ advantages, is that it has high efficiency on the adult worms of all medicinally significant Schistosoma species. In the meantime, its disadvantages are its inefficacy against the early phase of schistosomiasis infection.⁶ In addition, depending on a single drug as the only medicine, even if morbidity is reduced, led to high concerns regarding the evolution of drug resistant schistosomes.⁷ This emphasized the necessity to look for the next generations of anti-schistosomal drugs. Consequently, a great deal of studies has urged the need for new drugs.⁸ S. mansoni and S. haematobium found primarily across Africa were used to infect the golden hamsters while, Schistosoma japonicum found in the Middle East was excluded because, its entire lifecycle would be covered in the vertebrate host.⁹

In nanotechnology the use of nanoparticles (NPs) in medical research is growing rapidly.¹⁰ Nanomaterials
A novel treatment of schistosomiasis: nano-calcium silicate incorporating 5% copper oxide

**Materials and Methods**

**Material preparation**

The present material that was prepared according to the wollastonite composition (CaSiO$_3$, CaO = 48.28g and SiO$_2$ = 51.72g) with doping 5%CuO was added to the solution. The calcium silicate incorporating CuO was prepared via wet method from calcium carbonate (CaCO$_3$, El-Gomhouria Company for Trading Chemicals and Medical Appliances, Cairo, Egypt), silicon gel (SiO$_2$, amorphous, Fluka [Fluka Chemie GmbH, Parent company Sigma-Aldrich, Buchs, Switzerland]) and copper carbonate [Cu$_2$CO$_3$(OH)$_2$, Fluka]. The succeeding reaction can be clarified by the following equations:

- $\text{CaCO}_3 + \text{HNO}_3 \rightarrow \text{CaNO}_3 \text{ in solution}$
- $\text{CaNO}_3 + \text{amorphous SiO}_2 \text{ in solution} \rightarrow \text{CaSiO}_3$ (in solution - base) (1)
- $\text{Cu}_2\text{CO}_3(\text{OH})_2$ [calculated as CuO 5%] + HNO$_3$ $\rightarrow$ CuNO$_3$ in solution

From (1) and (2)

- $\text{CaSiO}_3(\text{base}) \text{ in solution} + \text{CuNO}_3 \text{ in solution}$

The CaSiO$_3$/CuO was dried at 100°C, calcined at 550°C for two hours then ball milled into powder. X-ray diffraction analysis (XRD) show the crystallization of quartz [oxide mineral, (SiO$_2$)] with little wollastonite (CaSiO$_3$), Ca olivine (Ca$_2$SiO$_4$) and tenorite (CuO). The microstructure (SEM and TEM) revealed the development of nano-particles (Figure 1).

The morphology of the CS-5%CuO was examined via scanning electron microscopy (SEM) (JEOL JXA-840A, Electron Probe Micro-Analyzer, Japan) at 15 kV. Nanoparticles were coated with gold, then examined via SEM apparatus. Particle size of the CS-5%CuO was measured by transmission electron microscopy (TEM; JEOL, Japan, JEM2100, ELECTRON MICROSCOPE, TEM-HR). A small quantity of the nanoparticles was dispersed in ethanol, then few milliliters of the solution were dropped onto a copper grid and TEM image was achieved.

**Animal infection by cercarie**

The in vivo research protocol followed the guidelines of the National Institutes of Health (NIH) Guide for Care and Use of Laboratory Animals (approval registration No. 16-254). Golden hamster (Mesocricetus auratus) were separately housed in plastic cages at room temperature, normal dark/light cycle and leftward to adapt for 5 days. Chow diet and water were provided. Surgical procedure was accomplished under sterile conditions using general anesthesia to suppress both reflex activity and muscle relaxation while losing consciousness. A ratio of ketamine and Bompun (3:1, Agar, Holland) was used for providing such combined effect of anesthesia. The anesthesia was injected intraperitoneally, and its dose was 0.02 mL/30 g hamster body weight. Then the stomach area of the anaesthetized hamster was shaved and ordered on a wooden rack cotton wool dipped in water for moistening the shaven area to permit the easy penetration of the cercarie. About 1 cm metal ring was placed on the shaven area of each hamster, then, a suspension consisting of roughly 250 living cercarie was dispensed in the metal...
ring using a micropipette at a period of 30 minutes for the cercarie to penetrate into the hamster.²⁴

**In vitro study**

To culture the parasites, adult worms were washed three times via Roswell Park Memorial Institute (RPMI) 1646 culture medium (BioWhittaker, Lonza, 3-MF Verviers, Belgium). The medium was supplemented with L-glutamine, 2090 fetal calf serum, and antibiotics (300 g streptomycin, 300 penicillin, and 160 g gentamycin per mL). Seven couples of worms were moved to each well of the 24 well culture plate (TPP, St. Louis, Mo) containing 1 mL of the same medium. Then 1 mL of tested material with concentrations (10, 5, 2.5, 1.25, 0.6, 0.3, 0.15 and 0.07 μg/mL) were added in each well excluding the negative control wells [media with dimethyl sulfoxide, (DMSO)] while, PZQ (10 μg/mL) was used as a positive control. The final size in each well was 2 mL. The plates were incubated at 37°C in a moist atmosphere containing 5% CO₃ (Thermo Fisher Scientific, Marietta, OH, USA) for 48 hours and monitored at different time intervals (2, 4, 6, 12, 24 and 48 hours). All steps were done in a sterilized laminar flow chamber. The experiment was done in a triplicate and repeated three times. After each incubation time, treated worms were examined for their mating (pairing), motility (worms motor activity changes) and death rate using an inverted optical Olympus microscope.

Worms showing no motility were counted as dead. Changes in worm’s motor activity of schistosomes were assessed qualitatively and their motor activity reduction was named as “slight” or “significant” overseeing the adult schistosomes in the *in vitro* experiment at all time intervals.

To observe morphological changes in the tegument of both adult worms, the samples were immediately processed.²⁵ The sample was fixed in equal volumes of glutaraldehyde 4% + cacodylate 0.2% for 2 hours. It was then washed in equal volumes of sucrose 0.4% and cacodylate 0.2% for 2 hours. Post fixed in equal volume of osmic acid 2% and cacodylate 0.3% for 1 hour, then washed with distilled water, finally dehydrated in ascending grades of ethyl alcohol for 5 minutes each (30%, 50%, 70% and 90%) then absolute alcohol (100%) for 19 minutes for 3 times. Then examined by Environmental Scanning Electron Microscope (SEM, Inspect S; FEI, Holland) at Electron Microscopy unit of Theodor Bilharz Research institute (TBJR, Embaba, Giza, Egypt).

**In vivo study**

**Liver perfusion**

For the *in vitro* bioassay, both *S. mansoni* and *S. haematobium* adult worms of Egyptian strains were brought from victimized infected golden hamsters following the technique of Stirewalt et al from hamster livers after eight weeks in *S. mansoni* and three months in *S. haematobium* of post infection.²⁶ Another infected animal group was used for *in vivo* assay.

**Animals**

A total of forty adult golden hamsters of weight 105-130 g were brought from the Schistosomla Biological Supply Center (SBSC) at Theodor Bilharz Research Institute (TBJR), Embaba, Giza, Egypt. The animals were divided into four groups. Each group comprised ten animals equally divided into two categories.

*Group (1): Negative control contained:*
- Non-infected and non-treated hamster
- Infected and non-treated hamster

*Group (2): Positive control contained:*
- Infected hamster with *S. mansoni* treated with 200 mg/kg PZQ (Positive control 1)
- Infected hamster with *S. haematobium* treated with 200 mg/kg PZQ (Positive control 2)

*Group (3): Contained:*
- Infected hamster with *S. mansoni* treated by CS-5%CuO
- Infected hamster with *S. haematobium* treated by CS-5%CuO

*Group (4): Contained:*
- Infected hamster with *S. mansoni* treated by calcium silicate without 5%CuO
- Infected hamster with *S. haematobium* treated by calcium silicate without 5%CuO

**Histopathological assessment**

After perfusion and retrieval of the specimens the liver, spleen and kidney were removed from infected treated and non-treated animals. As well as, the healthy organs from the control animals. All organ samples were preserved in 10% formalin for at least 2 weeks. An illustrative portion was brought and washed overnight to get rid of excess formalin. Tissues were dehydrated sequentially in increasing concentrations of alcohols of 50%, 80%, 90% and 96% at hourly stepped intervals.

Tissues were then cleared off alcohol twice into xylene. Infiltration with paraffin wax was accomplished for 3 hours in the paraffin wax oven set at 2°C below the melting point of wax.²⁷ Tissues were then emplaced in a fresh molten paraffin wax and left to dry. The tissues were sectioned at 0.7 mm thickness using a microtome, and placed in a hot oven for 15 mins. The tissue sections were de-waxed in xylene, rehydrated and stained with hematoxylin and eosin (H & E) dyes. The stained tissues were slipped with Distyrene plasticizer xylene (DPX), dried and tested microscopically for granulomas.²⁸

**The morphology of CS-5%CuO**

Figure 1 signifies the SEM micrograph and TEM image of the calcium silicate incorporating 5% CuO. They demonstrated backed fine rounded grains in the nano-scale size <50 nm which confirm the nanosize. The particle size of the prepared materials was found to be reliant on
the presence of the CuO, as their obtained particle size was (4.49-6.54 nm) in comparison with that of the pure calcium silicate whose particle size was (19.90-36.23 nm).

**Cytotoxicity**

Acute toxicity study was carried out to govern the LD50 of the nanoparticles using a graphical method. Using animal study, signs of toxicity and mortality within 24-72 hours were documented and the LD50 was calculated using the log-probit graph. The LD50 of the CS-5%CuO nanoparticles was 365.8760.36 (mg/kg).23

Cytotoxicity and cell viability assay was conducted on HFB4 (normal melanocyte). The cell line was obtained from ATCC (American Type Culture Collection). After 24 hours of seeding, the inspected cell line was cultured in a 96 well plate, the medium was changed to serum-free medium containing final concentration of the CS-5%CuO (100 µg/mL) in triplicates. Subsequently, cells were incubated for 2 days, doxorubicin (100 µg/mL) was used as a positive control and 0.5% dimethyl sulfoxide (DMSO) was used as a negative control. Cytotoxicity and cell viability were determined using the MTT (3-(4, 5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) assay. Cytotoxicity results revealed that the investigated nanoparticles are of low efficient on the normal melanocyte (HFB4) above 81.39%, which have been previously described by Mabrouk et al.23

**Anti-schistosomal activity**

The in vitro treatment efficacy of CS-5%CuO on adult worms of *S. mansoni* and *S. haematobium* depend greatly on their concentration (10, 5, 2.5, 1.25, 0.6, 0.3, 0.15 and 0.07 µg/mL). Almost ~95% of the worms had been separated within 2h in both 10, 5 and 2.5 µg/mL concentrations, although, about 85% of worms had been separated after 4h in both the 1.25 and 0.6 µg/mL concentrations, and at lower concentrations [i.e. 0.3 & 0.15 µg/mL] the separation was 60% after 6 hours. In case of concentration (0.07 µg/mL) the separation of the adult worms was after 12 hours. The known treated control (PZQ 10 µg/mL) caused separation of adult couple after 4 hours of incubations. However, the efficiency of the lowest concentrations (0.15 and 0.07 µg/mL) were lower than the higher concentrations as presented in Figures 2 and 3.

During tracing of the parasite motility, a marked decrease in the parasitic movements was noticed in most concentrations. The percentage of worms with reduction in motility was directly proportional to the concentration and to the incubation period. A slight decrease in the motor activity was detected after 2 hours of incubation for all adult worms exposed to 10, 5 and 2.5 (µg/mL), while, total motility loss happened after 4, 6 and 12 hours, respectively. Other concentrations began to reduce the movement of worms after 12 hours without clear motility loss. Conversely, PZQ (10 µg/mL) after 2 hours of incubation decreased the motor activity while, after 4h interval, all worms showed complete loss of motor activity. Indeed, the exposure time is a concentration dependent where, at 6 hours CS-5%CuO exposure, both types of worms’ species were 100% destroyed by 10 µg/mL. Whereas, at concentrations of 5 and 2.5 µg/mL the time was extended to 12 hours and 24 hours, respectively, for *S. mansoni* (Figure 2), and to 12 h for each of the two previous concentrations against *S. haematobium* (Figure 3). Furthermore, the effect of 1.25 µg/mL on both worms’ species was similar to a death rate of 100% after 48 h time exposure. Our results delineated that the male worms of both schistosomes were more sensitive against the tested material than the female ones. While, PZQ treated group displayed total death of parasites (100%) after 6h of incubation. Negative control groups were still living at 48 hours of incubation which was considered the end point of the experiment. At 1.25 µg/mL concentration, the anti-schistosomal effect began to appear after 12 hours of incubation, and the effect was time dependent (Figures 2
and 3). At lower concentration of 0.6 μg/mL, the effect of the substance began to appear after 24 and 48 hours, while at concentration 0.3 μg/mL, the effect of the CS-5%CuO began to appear after 48 hours with moderate activity. In case of concentration 0.07 μg/mL, no anti-schistosomal effect was recorded.

SEM examination from non-treated golden hamster revealed that, the oral sucker in both Schistosoma were oval-shape, covered with sharp spines varying in size. But, for the ventral sucker they were rounded, covered with the spine. The ventral surface behind the ventral sucker increases in width and folds ventrally to form the gynaecophoric canal. The dorsal surface of worms was provided with numerous large tubercles bearing spines. The zones between the tubercles were lacking spines. The ventral side of the worm was provided with rows of minute spines. The tegument surrounding the tubercles was wrinkled (Figure 4).

Clear tegmental changes of S. mansoni adult worms in the golden hamster appeared after treatment with CS-5%CuO. Similarly, ultra-morphological variations were observed in both males and females adult schistosomas after 48h incubation in vitro with concentrations 10%, 5%, 2.5%, 1.25%, 0.6%, 0.3%, 0.15% and 0.07% from CS-5%CuO. In comparison with untreated parasite there was no any change (Figure 3), tegmental morphological alterations clear for the parasites exposed to CS-5%CuO with variation in the effect relative to the dose ratio of CS-5%CuO. On the other side, the known treatment by PZQ revealed similar tegmental alteration in 100% of Schistosoma worms (Figure 5).

**Treatment of S. mansoni and S. haematobium**

The morphological changes were clear in the male of both S. mansoni and S. haematobium since it showed abnormalities in the tubercles, and spine damage (destruction, peeling of spines, tubercles, and tegument peeling or sloughing) specifically on its dorsal surface. The manifestation of bubbles surrounding the morphologically altered tubercles was observed as well as sucker alteration or destruction. The oral sucker of some worms was distorted. While in females the tegument scaling, wrinkling, and erosion (contraction and peeling of dorsal region) and suckers’ alterations or destruction were noticed (Figures 6 and 7).

**Histopathological assessment**

Histological examination of kidney, liver and spleen sectors of control group (healthy group) using light microscopy have been established. It revealed that, the cortical parenchyma of the kidney contains a number of renal corpuscles together with proximal and distal renal tubules (X200) (Figure 8). In addition, liver hepatocytes extended from the central vein to the periphery of the hepatic lobules and the portal tract was shown at X100 (Figure 6). However, the spleen presented with a normal architecture, consisted of white and red pulps enveloped by a capsule of dense connective tissue. The white pulp consisted of a central, T-cell rich zone, and a periarterial lymphoid sheath enclosed by B-cell-rich primary follicles. The marginal sinus disconnected the white pulp from the red pulp. Marginal sinus was embedded in a layer of marginal zone lymphocytes (X100) (Figure 8).

However, the effect of the parasite on infected untreated control group, showed no obvious effect on the kidney,
A novel treatment of schistosomiasis: nano-calcium silicate incorporating 5% copper oxide
Advanced Pharmaceutical Bulletin, 2021, Volume 11, Issue 1

Nevertheless there was an effect on both the liver and the spleen that revealed pathological chronic granulomatous lesions in the hepatic parenchyma. Such lesions were formed of several bilharzial eggs containing miracidia, enclosed by abundant chronic inflammatory cells in the form of epithelioid cells, lymphocytes, plasma cells, macrophages, and eosinophils forming granuloma accompanied with severe fibrosis (Figure 9). Also, the spleen showed ova surrounded by inflammatory cellular reaction and the borders in between white and red pulp began to fade. Roughly splenic cells were evaluated. Most advanced cells were darkly stained with big sinusoidal spaces.

Histological liver sections treated with CS-5% CuO exhibited diffuse infiltration of liver parenchyma via chronic inflammatory cells devoid of observed eggs or fibrosis regions (Figure 10). Absence of bilharzial eggs and fibrosis with substantial reduction of liver parenchyma infiltration by the chronic inflammatory cells was revealed. On the other hand, spleen sections exhibited more or less degeneration of ova, surrounded by lympho-epithelioid cellular inflammatory cellular infiltration.

Discussion
In tropical regions, schistosomiasis is a parasitic disease that affects human health. World Health Organization (WHO) provided a program for studying the development of new anti-parasitic drugs and encourages worldwide synthesis of new compounds for these parasitic diseases.39 Previous studies exhibited the effectiveness of using nano particles of calcium silicate CS-CuO to fight bacteria and fungus. Clusters containing 5% CuO showed inhibition zone diameter (IZD) in the range of 30 and 22 mm, respectively. Other clusters containing 3% CuO showed IZD of 20 mm. Clusters of wollastonite with/without CuO prepared via wet precipitation route can be considered as a novel antimicrobial agent for bone implantation.30 In contrast, calcium silicate incorporating CuO effectively motivated bone regeneration. Also, it was postulated that the CS-CuO materials is recommended for treatment of cancer. The upcoming triumph of copper incorporation into compounds in the clinic demands make an link between biomedical scientists, clinicians and likewise chemists.31 In the present study, different concentrations of CS-5% CuO against S. mansoni and S. haematobium (Egyptian strains) were experimentally assessed in vitro and in vivo in infected golden hamster. To the best of our knowledge, this study may be the first investigating the efficacy of CS-5% CuO against Egyptian Schistosoma strains. Our results revealed that, CS-5% CuO especially at concentration 10, 5 and 2.5 (μg/mL) showed strong anti-schistosomal activity against male and female of S. mansoni and S. haematobium. Nanomaterials play a vital role in the treatment of many parasitic diseases.32 Dkhil

Figure 8. Histological section of negative control (Healthy control) staining with H & E: a) Control kidney showing normal cortical structure (X200). b) Control liver showing normal hepatic lobular architecture (X100). c) Control Spleen showing normal architecture (X100).

Figure 9. Histological section of infected untreated control staining with H & E: a) Spleen revealed aggregate of deposited bilharzia ova, surrounded by lympho-epithelioid tissue reaction (X200). b) Liver showing multiple egg and a worm impacted inside a portal vein (X100).

Figure 10. Histological section of infected treated group staining with H & E: a) Liver showing calcified SH ova, mostly engulfed by multinucleated giant cells, with little disturbance of hepatic lobular architecture (X200). b) Liver showing epithelioid egg granuloma (X200). c) Spleen showing many fresh deposited and degenerated SH ova (X200). d) Spleen showing some degenerated ova, surrounded by lympho-epithelioid cellular inflammatory cellular infiltration (X200).
et al examined the influence of selenium nanoparticles (Se-NPs) on mice infected by schistosome. Se-NPs ameliorated the hepatic histopathology and reduced the granulomas diameters. Furthermore, this treatment increased the glutathione level while; the levels of nitrite/nitrate and malondialdehyde were significantly decreased. DKhil et al, in 2017 explained, the role of gold nanoparticles (Au-NPs) in contradiction of splenic injury in mice infected with S. mansoni. The treatment of mice with gold NPs reduced the extent of histological impairment and oxidative stress in the spleen tissue. Lately, Dkhil et al concluded the curative effects of NPs related to their antioxidant activities; consequently, they proved their anti-schistosomal activities in mice. Oliveira et al proposed different strategy to prompt protection against S. mansoni infection by creating a vaccine founded on chitosan nanoparticles together with the antigen SmRho coated with alginate. It was capable of modulating the granuloma area that signifies the major pathological response in schistosomiasis and also to encourage the defense against infection S. mansoni. Our results are matching with other studies which inspected the effect of anti-schistosomal drug against tegument of schistosomes. The changes caused by CS-5%CuO was more noticeable in male tegument than that in females. These findings were in agreement with the findings of Staudt et al. This may be elucidated by the point that most of the female’s body is walled in the gynaecophoric duct of the male [i.e., not in direct contact with the host’s microenvironment].

The alteration in the surface architecture of S. mansoni and S. haematobium worms as a result of treatment with CS-5%CuO were more or less like the tegmental alterations in Schistosoma mekongi worms sheltered in mice treated with artesunate (C18H20O6) as observed by Jirunagoonskul et al or that studied by Staud et al on the effects of the enantiomers of PZQ and its main metabolite on in vitro S. mansoni. The current results revealed that the morphological alterations could be a mechanism for killing the worms using CS-CuO. Strong damage to the suckers led to the loss of the parasite ability to stick to the blood vessels and rendered the difficulty of ingestion of nutrients from the blood. Furthermore, the damage to the worm’s body tegument would destroy the defense system of the worm, so that it could easily be attacked by immune system of the host. On the other hand, the in vivo anti-schistosomal activity of CS-CuO on both strains of infected hamster was evaluated concerning histopathological changes in liver, spleen and kidney. The results showed that, both liver and spleen tissues showed strong damage in infected untreated control, but kidney was not affected. This affection may be attributed to the demolition in the hepatic tissue leading to the incapability of the liver to metabolize proteins and fats, or else to consume glucose and store glycogen. On the contrary, CS-5%CuO treated groups showed marked improvement on both liver and spleen tissues. Our results are in agreement with other researchers. Histopathology of the liver and spleen of the CS-CuO cured hamsters showed fewer granulomas than in non-treated group. Other results by Wynn and Cheever, 2007 stated that the reduction of granuloma diameter might be attributed to the reduction of type III procollagen which is in charge of the granuloma’s creation. We could also clarify that, the reduction of granuloma size by CS-CuO may be owing to the suppression of the T helper (TH) cell differentiation (Th1 and Th2) lymphocytes and their cytokines. Such suppression may facilitate the formation and development of granuloma.

Khalil et al studied the effect of iron nanoparticles on adult worms of Schistosoma mansoni using different concentrations of 30 and 60 mg/L. Their results exhibited activity on worms, and that the mortality rate in the concentration of 30 mg/L was 15%, 20% and 100% after incubation period of 2, 3 and 12 hours, respectively. While for the concentration of 60 mg/L, it recorded 55%, 65%, 77% and 100% after incubation period of 1, 2, 3 and 48 hours, respectively. In 2012, Luz et al assessed the in vitro anti-schistosomal activity of curcumin combined with nanoparticles of poly (lactic glycolic acid) (PLGA) with a 100% mortality rate at 50 and 100 50μm after 12 and 24 hours of incubation, respectively. It led to a decrease in motor activity after 12 hours of incubation at 40μm and 30μm. Besides, at concentrations 40μm of the curcumin loaded with PLGA nanoparticles caused partial changes in adult integument, presence of alteration and structural vesicles after 48 hours of incubation. As a result, CS-5%CuO may become a pioneering treatment for schistosomiasis.

Conclusion
The results declare that CS-5%CuO exhibited excellent anti-schistosomal activities on both in vitro and in vivo experiments for both strains of Egyptian schistosomes. The most potential effect of CS-5%CuO was exhibited after 6 hours by 10 μg/mL with significant activity of (P value = 0.001). Consequently, calcium silicate incorporating CuO may become a novel talented candidate for the development of new schistosomiasis treatments.

Conflict of Interest
Authors confirm that there are no conflicts of interest.

Ethical Issues
The in vivo research protocol was reviewed and approved by the Animal Care Committee of the National Research Centre, Egypt, which follows the guidelines of the National Institutes of Health (NIH) Guide for Care and Use of Laboratory Animals (approval registration No. 16-254).

References
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J.
A novel treatment of schistosomiasis: nano-calcium silicate incorporating %5 copper oxide

Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 2006;6(7):411-25. doi: 10.1016/S1473-3099(06)70521-7

2. Tekwu EM, Anyan WK, Boamah D, Balfour-Awuaa KO, Keyet Tekwu S, Penlap Beng V, et al. Mechanically produced schistosomula as a higher-throughput tool for phenotypic pre-screening in drug sensitivity assays: current research and future trends. *Biomark Res* 2016;4:21. doi: 10.1186/s40364-016-0075-2

3. Grysseels B. Schistosomiasis. * Infect Dis Clin North Am* 2012;26(2):383-97. doi: 10.1016/j.idc.2012.03.004

4. Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, Gärnert F, Correia da Costa JM. Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. *Antimicrob Agents Chemother* 2017;61(5). doi: 10.1128/aac.02582-16

5. Fenwick A. Praziquantel: do we need another antischistosoma treatment? *Future Med Chem* 2015;7(6):677-80. doi: 10.4155/fmc.15.16

6. WHO/ Department of control of neglected tropical diseases. Schistosomiasis: number of people treated worldwide in 2013. WHO; 2015. Available from: https://www.who.int/schistosomiasis/resources/who_wer9005/en/.

7. Friedman JE, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM. Praziquantel for the treatment of schistosomiasis during human pregnancy. *Bull World Health Organ* 2018;96(1):59-65. doi: 10.2471/blt.17.198879

8. Secor WE, Montgomery SP. Something old, something new: is praziquantel enough for schistosomiasis control? *Future Med Chem* 2015;7(6):681-4. doi: 10.4155/fmc.15.9

9. Pica-Mattoccia L, Cioli D. Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. *Int J Parasitol* 2004;34(4):527-33. doi: 10.1016/j.ijpara.2003.12.003

10. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica-Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. *Parasitology* 2009;136(13):1825-35. doi: 10.1017/s0031182009000493

11. Gouveia MJ, Brindley PJ, Gärnert F, Costa J, Vale N. Drug repurposing for schistosomiasis: combinations of drugs or biomolecules. *Pharmaceuticals (Basel)* 2018;11(1). doi: 10.3390/ph11010015

12. Sarkar S, Osaka K, Jamal QMS, Kamal MA, Sayeed U, Khan MKA, et al. Advances and implications in nanotechnology for lung cancer management. *Curr Drug Metab* 2017;18(1):30-8. doi: 10.2174/138920201866616111

13. Khan I, Khan M, Umar MN, Oh DH. Nanobiotechnology and its applications in drug delivery system: a review. *IET Nanobiotechnol* 2015;9(6):396-400. doi: 10.1049/iet-nbt.2014.0062

14. Debbage P. Targeted drugs and nanomedicine: present and future. *Curr Pharm Des* 2009;15(2):153-72. doi: 10.2174/1381612097878002870

15. Colino CI, Millán CG, Lanoa JM. Nanoparticles for signaling in biodiagnosis and treatment of infectious diseases. *Int J Mol Sci* 2018;19(6). doi: 10.3390/ijms19061627

16. Roduner E. Size matters: why nanomaterials are different. *Chem Soc Rev* 2006;35(7):583-92. doi: 10.1039/b502142c

17. Jia L. Nanoparticle formulation increases oral bioavailability of poorly soluble drugs: approaches experimental evidences and theory. *Curr Nanosci* 2005;1(3):237-43. doi: 10.2174/157314305774642939

18. Ambrogio MW, Thomas CR, Zhao YL, Zink JL, Stoddart JF. Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. *Acc Chem Res* 2011;44(10):903-13. doi: 10.1021/ar200018x

19. Armstead AL, Li B. Nanomedicine as an emerging approach against intracellular pathogens. *Int J Nanomedicine* 2011;6:3281-93. doi: 10.2147/ijn.s22785

20. Rahman K, Khan SU, Fahad S, Chang MX, Abbas A, Khan WU, et al. Nano-biotechnology: a new approach to treat and prevent malaria. *Int J Nanomedicine* 2019;14:1401-10. doi: 10.2147/ijn.s190692

21. Norouzi R. A review on most nanoparticles applied against parasitic infections. *J Biol Today's World* 2017;6(10):196-203. doi: 10.15412/j.jbtw.01061003

22. Murthy HCA, Abebe B, Desalegn T, Prakash CH, Shantaveerayya K. A review on green synthesis of Cu and CuO nanomaterials for multifunctional applications. *Mater Sci Res India* 2018;15(3):279-95. doi: 10.13005/mri/150311

23. Mabrouk M, ELShehiney SA, Kenawy SH, EL-Bassyouni GT, Hamzaw EM. Novel, cost-effective, Cu-doped calcium silicate nanoparticles for bone fracture intervention: Inherent bioactivity and in vivo performance. *J Biomed Mater Res B Appl Biomater* 2019;107(2):388-99. doi: 10.1002/jbmr.b34130

24. Smithers SR, Terry RJ. The infection of laboratory hosts with cercariae of *Schistosoma mansoni* and the recovery of the adult worms. *Parasitology* 1965;55(4):695-700. doi: 10.1017/s0031182000086248

25. Glaevert AM. The high voltage electron microscope in biology. *J Cell Biol* 1974;63(3):717-48. doi: 10.1083/jcb.63.3.717

26. Stirewalt MA, Cousin CE, Dorsey CH. *Schistosoma mansoni*: stimulus and transformation of cercariae into schistosomules. *Exp Parasitol* 1983;56(3):358-68. doi: 10.1016/0041-894X(83)90081-4

27. Baker M, Johnson K, Roberts I. Passive arguments raised. *Linguist Inq* 1989;20(2):219-51

28. Farah MJ, Rabinowitz C, Quinn GE, Liu GT. Early commitment of neural substrates for face recognition. *Cogn Neuropsychol* 2000;17(1):117-23. doi: 10.1080/026432900380526

29. Dias LC, Dessoy MA, Silva JJN, Thiemann OH, Oliva G, Andricopulo AD. [Chemotherapy of Chagas' disease: state of the art and perspectives for the development of new drugs]. *Quim Nova* 2009;32(9):2444-57. doi: 10.1590/S0100-40422009000900038

30. Abd El-Aty AA, Kenawy SH, EL-Bassyouni GT, Hamzaw EM. CuO doped wollastonite clusters for some antimicrobial and anti-fungi applications. *Pharm Lett* 2018;10(5):42-54.

31. Mabrouk M, Kenawy SH, EL-Bassyouni GE, Ibrahim Soliman AAE, Aly Hamzaw EM. Cancer cells treated by clusters of copper oxide doped calcium silicate. *Adv Pharm Bull* 2019;9(1):102-9. doi: 10.15171/apb.2019.013

32. Dkhil MA, Bauomy AA, Diab MSM, Al-Quraishy S. Protective role of selenium nanoparticles against *Schistosoma mansoni* induced hepatic injury in mice.
33. Dkhil MA, Khalil MF, Diab MSM, Bauomy AA, Al-Quraishy S. Effect of gold nanoparticles on mice splenomegaly induced by schistosomiasis mansoni. Saudi J Biol Sci 2017;24(6):1418-23. doi: 10.1016/j.sjbs.2016.12.017

34. Dkhil MA, Khalil MF, Diab MSM, Bauomy AA, Santourlidis S, Al-Shaebi EM, et al. Evaluation of nanoselenium and nanogold activities against murine intestinal schistosomiasis. Saudi J Biol Sci 2019;26(7):1468-72. doi: 10.1016/j.sjbs.2018.02.008

35. Oliveira CR, Rezende CM, Silva MR, Borges OM, Pêgo AP, Goes AM. Oral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection. ScientificWorldJournal 2012;2012:938457. doi: 10.1100/2012/938457

36. Bucther V, Hess J, Gasser G, Keiser J. Assessment of tegumental damage to Schistosoma mansoni and S. haematobium after in vitro exposure to ferrocenyl, ruthenocenyl and benzyl derivatives of oxamniquine using scanning electron microscopy. Parasit Vectors 2018;11(1):580. doi: 10.1186/s13071-018-3132-x

37. Staudt U, Schmadl G, Blaschke G, Mehlhorn H. Light and scanning electron microscopy studies on the effects of the enantiomers of praziquantel and its main metabolite on Schistosoma mansoni in vitro. Parasitol Res 1992;78(5):392-7. doi: 10.1007/bf00931694

38. Mostafa OMS, Soliman MI. Ultrastructural alterations of adult male Schistosoma mansoni harbored in albino mice treated with Sidr honey and/or Nigella sativa oil. J King Saud Univ Sci 2010;22(3):111-21. doi: 10.1016/j.jksus.2010.03.001

39. Jiraungkoorskul W, Sahaphong S, Sobhon P, Riengrojpitak S, Kangwanrangsan N. Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harbourced in mice. Parasitol Int 2005;54(3):177-83. doi: 10.1016/j.parint.2005.04.001

40. Xiao SU, Utzinger J, Shen BG, Tanner M, Chollet J. Ultrastructural alterations of adult Schistosoma haematobium harbored in mice following artemether administration. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2006;24(5):321-8

41. El-kott AF, Mohammed RT, Ismail NR. Efficacy of garlic and Mirazid in treatment of the liver granuloma in mice infected with Schistosoma mansoni. Res J Parasitol 2011;6(5):151-9. doi: 10.3923/pjpr.2011.151.159

42. Riad NHA, Fares NH, Mostafa OMS, Mahmoud YI. The effect of garlic on some parasitological and on hepatic tissue reactions in experimental Schistosomiasis mansoni. J Appl Sci Res 2007;3(10):949-60

43. Wynn TA, Cheever AW. Cytokine regulation of granuloma formation in schistosomiasis. Curr Opin Immunol 1995;7(4):505-11. doi: 10.1016/0952-7915(95)80095-6

44. Khalil LMM, Azzam AM, Mohamed HAM, Nigm AH, Taha HA, Soliman MI. In vitro effects of iron nanoparticles on Schistosoma mansoi adult worms and its intermediate host snail, Biomphalaria alexandrina. J Egypt Soc Parasitol 2018;48(2):363-8. doi: 10.12816/0050443

45. Luz PP, Magalhães LG, Pereira AC, Cunha WR, Rodrigues V, Andrade ESML. Curcumin-loaded into PLGA nanoparticles: preparation and in vitro schistosomicidal activity. Parasitol Res 2012;110(2):593-8. doi: 10.1007/s00436-011-2527-9